Found: 70
Select item for more details and to access through your institution.
Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 19, p. 3344, doi. 10.1002/cncr.35384
- By:
- Publication type:
- Article
Characteristics and outcomes of patients with relapsed Philadelphia chromosome‐positive acute lymphoblastic leukemia after failure of a frontline ponatinib‐containing therapy.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 7, p. 1423, doi. 10.1002/ajh.27329
- By:
- Publication type:
- Article
The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment‐free remission in chronic myeloid leukemia.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 6, p. 1175, doi. 10.1002/ajh.27307
- By:
- Publication type:
- Article
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 4, p. 792, doi. 10.1002/ajh.27236
- By:
- Publication type:
- Article
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 11, p. 1780, doi. 10.1002/ajh.27070
- By:
- Publication type:
- Article
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre‐ and post‐ponatinib era.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 10, p. 1619, doi. 10.1002/ajh.27037
- By:
- Publication type:
- Article
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT‐PCR for BCR::ABL1.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 8, p. 1196, doi. 10.1002/ajh.26949
- By:
- Publication type:
- Article
The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR::ABL1 tyrosine kinase inhibitors.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 4, p. 658, doi. 10.1002/ajh.26852
- By:
- Publication type:
- Article
Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 4, p. 639, doi. 10.1002/ajh.26836
- By:
- Publication type:
- Article
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 12, p. 1560, doi. 10.1002/ajh.26724
- By:
- Publication type:
- Article
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD‐negative remission.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 11, p. E408, doi. 10.1002/ajh.26698
- By:
- Publication type:
- Article
Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 11, p. 1413, doi. 10.1002/ajh.26689
- By:
- Publication type:
- Article
Treatment‐free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 7, p. 856, doi. 10.1002/ajh.26550
- By:
- Publication type:
- Article
Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome‐negative B‐cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 6, p. E201, doi. 10.1002/ajh.26526
- By:
- Publication type:
- Article
Development of TP53 mutations over the course of therapy for acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 11, p. 1420, doi. 10.1002/ajh.26314
- By:
- Publication type:
- Article
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 6, p. 612, doi. 10.1002/ajh.25769
- By:
- Publication type:
- Article
NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1‐mutated acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 6, p. E158, doi. 10.1002/ajh.25454
- By:
- Publication type:
- Article
Poor outcomes associated with +der(22)t(9;22) and −9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 3, p. 238, doi. 10.1002/ajh.24625
- By:
- Publication type:
- Article
Comprehensive immunophenotypic study of acute myeloid leukemia with KMT2A (MLL) rearrangement in adults: A single‐institution experience.
- Published in:
- Cytometry. Part B, 2022, v. 102, n. 2, p. 123, doi. 10.1002/cyto.b.22051
- By:
- Publication type:
- Article
Emergence of BCR – ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series.
- Published in:
- Frontiers in Oncology, 2020, v. 11, p. N.PAG, doi. 10.3389/fonc.2020.588876
- By:
- Publication type:
- Article
PPP1R7 Is a Novel Translocation Partner of CBFB via t(2;16)(q37;q22) in Acute Myeloid Leukemia.
- Published in:
- Genes, 2022, v. 13, n. 8, p. 1367, doi. 10.3390/genes13081367
- By:
- Publication type:
- Article
Nucleophosmin 1 Mutations in Acute Myeloid Leukemia.
- Published in:
- Genes, 2020, v. 11, n. 6, p. 649, doi. 10.3390/genes11060649
- By:
- Publication type:
- Article
Using Proton Pump Inhibitors is not Associated With Adverse Outcomes in Patients With Chronic Myeloid Leukemia Treated With Dasatinib.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 7, p. 484, doi. 10.1016/j.clml.2024.02.014
- By:
- Publication type:
- Article
Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 11, p. e369, doi. 10.1016/j.clml.2023.08.001
- By:
- Publication type:
- Article
Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 10, p. 742, doi. 10.1016/j.clml.2023.05.009
- By:
- Publication type:
- Article
CML-375: AIM4CML Trial in Progress: A Phase IIIb Study of Asciminib Monotherapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with and without T315I Mutations.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S334, doi. 10.1016/S2152-2650(21)01782-1
- By:
- Publication type:
- Article
Poster: CML-375: AIM4CML Trial in Progress: A Phase IIIb Study of Asciminib Monotherapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with and without T315I Mutations.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S224, doi. 10.1016/S2152-2650(21)01410-5
- By:
- Publication type:
- Article
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00915-6
- By:
- Publication type:
- Article
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00871-1
- By:
- Publication type:
- Article
Management of chronic myeloid leukemia in 2023 – common ground and common sense.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00823-9
- By:
- Publication type:
- Article
Management of chronic myeloid leukemia in 2023 – common ground and common sense.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00823-9
- By:
- Publication type:
- Article
Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 10, p. 1, doi. 10.1038/s41408-022-00742-1
- By:
- Publication type:
- Article
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 9, p. 1, doi. 10.1038/s41408-021-00557-6
- By:
- Publication type:
- Article
Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 6, p. 1, doi. 10.1038/s41408-021-00497-1
- By:
- Publication type:
- Article
Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 5, p. 1, doi. 10.1038/s41408-020-0329-y
- By:
- Publication type:
- Article
Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 5, p. 1, doi. 10.1038/s41408-020-0318-1
- By:
- Publication type:
- Article
Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 5, p. 1, doi. 10.1038/s41408-020-0316-3
- By:
- Publication type:
- Article
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
- Published in:
- Journal of Hematology & Oncology, 2023, v. 16, n. 1, p. 1, doi. 10.1186/s13045-023-01476-8
- By:
- Publication type:
- Article
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.
- Published in:
- Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01229-z
- By:
- Publication type:
- Article
Calibration-free NGS quantitation of mutations below 0.01% VAF.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-26308-6
- By:
- Publication type:
- Article
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 15, p. 2652, doi. 10.1002/cncr.35317
- By:
- Publication type:
- Article
Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 11, p. 1964, doi. 10.1002/cncr.35251
- By:
- Publication type:
- Article
Reply to "Impact of obesity surgery on tyrosine kinase inhibitor responses and survival outcomes in patients with chronic myeloid leukemia: Further data are still warranted!".
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 14, p. 2268, doi. 10.1002/cncr.34834
- By:
- Publication type:
- Article
Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation.
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 12, p. 1856, doi. 10.1002/cncr.34728
- By:
- Publication type:
- Article
Association between bariatric surgery and outcomes in chronic myeloid leukemia.
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 12, p. 1866, doi. 10.1002/cncr.34725
- By:
- Publication type:
- Article
Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome–positive acute lymphoblastic leukemia treated with hyper‐CVAD and dasatinib.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 15, p. 2641, doi. 10.1002/cncr.33539
- By:
- Publication type:
- Article
Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 14, p. 2489, doi. 10.1002/cncr.33508
- By:
- Publication type:
- Article
Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis
- Published in:
- Cancer (0008543X), 2019, v. 125, n. 15, p. 2579, doi. 10.1002/cncr.32139
- By:
- Publication type:
- Article
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease.
- Published in:
- British Journal of Haematology, 2024, v. 205, n. 1, p. 30, doi. 10.1111/bjh.19519
- By:
- Publication type:
- Article